QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.52 (+3.61%)
NIO   5.33 (-7.79%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.01 (+1.49%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
NASDAQ:PCVX

Vaxcyte (PCVX) Stock Price, News & Analysis

$71.55
-0.16 (-0.22%)
(As of 04:00 PM ET)
Today's Range
$70.49
$71.98
50-Day Range
$59.79
$81.05
52-Week Range
$34.11
$82.04
Volume
620,367 shs
Average Volume
976,161 shs
Market Capitalization
$7.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.50

Vaxcyte MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
10.1% Upside
$78.50 Price Target
Short Interest
Bearish
9.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.80mentions of Vaxcyte in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$7.86 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.16) to ($4.51) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.48 out of 5 stars

Medical Sector

941st out of 948 stocks

Biological Products, Except Diagnostic Industry

158th out of 158 stocks


PCVX stock logo

About Vaxcyte Stock (NASDAQ:PCVX)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Stock Price History

PCVX Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Reviewing BioNTech (NASDAQ:BNTX) & Vaxcyte (NASDAQ:PCVX)
TD Cowen Remains a Buy on Vaxcyte (PCVX)
Vaxcyte Stock (NASDAQ:PCVX), Short Interest Report
5 Best Russell 2000 Stocks To Buy According To Hedge Funds
Vaxcyte (NASDAQ:PCVX) Hits New 12-Month High at $77.26
Vaxcyte (PCVX) Set to Announce Quarterly Earnings on Tuesday
PCVX Apr 2024 50.000 call
PCVX Sep 2024 40.000 put
PCVX Mar 2024 90.000 call
PCVX Mar 2024 60.000 put
PCVX Feb 2024 80.000 call
See More Headlines
Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/04/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PCVX
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.50
High Stock Price Target
$95.00
Low Stock Price Target
$69.00
Potential Upside/Downside
+9.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-402,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.04 per share

Miscellaneous

Free Float
104,505,000
Market Cap
$7.77 billion
Optionable
Optionable
Beta
0.91
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















PCVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings
or view top-rated stocks.

What is Vaxcyte's stock price target for 2024?

5 analysts have issued 12 month price targets for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they predict the company's stock price to reach $78.50 in the next year. This suggests a possible upside of 10.1% from the stock's current price.
View analysts price targets for PCVX
or view top-rated stocks among Wall Street analysts.

How have PCVX shares performed in 2024?

Vaxcyte's stock was trading at $62.80 at the start of the year. Since then, PCVX shares have increased by 13.5% and is now trading at $71.29.
View the best growth stocks for 2024 here
.

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PCVX earnings forecast
.

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.82) EPS for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same quarter in the prior year, the business posted ($0.73) EPS.

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).

When did Vaxcyte IPO?

(PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.88%), Capital Research Global Investors (3.62%), Price T Rowe Associates Inc. MD (2.81%), Jennison Associates LLC (1.55%), Westfield Capital Management Co. LP (1.53%) and Braidwell LP (1.36%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman and Paul Sauer.
View institutional ownership trends
.

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PCVX) was last updated on 3/4/2024 by MarketBeat.com Staff